This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

YM758

Cardeus Pharmaceuticals, Inc.

Drug Names(s): YM758

Description: YM758 is an If channel inhibitor.

Deal Structure: Astellas and Cardeus
In March 2011, Astellas announced that it has entered into an exclusive license agreement with Cardeus to develop, manufacture and commercialize three Astellas compounds in all territories excluding Japan.

Under the terms of agreement, two clinical stage compounds, Y758 and ASP6537, as well as one preclinical stage compound are licensed to Cardeus. Cardeus is responsible for all the development, manufacturing and commercialization activities and associated costs. In addition, Astellas is entitled to receive an upfront payment, development and sales milestone payments together with royalties on sales. Also, with regard to Caredus' future partnering activities on three compounds, Astellas is granted rights of first negotiation for the U.S. and European markets and rights of first refusal for China market.

Partners: Astellas Pharma, Inc.


YM758 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug